Kazuo Fujihara
#148,908
Most Influential Person Now
Researcher
Kazuo Fujihara's AcademicInfluence.com Rankings
Kazuo Fujiharacomputer-science Degrees
Computer Science
#7686
World Rank
#8090
Historical Rank
Computational Linguistics
#1583
World Rank
#1600
Historical Rank
Machine Learning
#2922
World Rank
#2958
Historical Rank
Artificial Intelligence
#3218
World Rank
#3265
Historical Rank
Download Badge
Computer Science
Kazuo Fujihara's Degrees
- PhD Computer Science University of Tokyo
- Masters Computer Science University of Tokyo
- Bachelors Computer Science University of Tokyo
Similar Degrees You Can Earn
Why Is Kazuo Fujihara Influential?
(Suggest an Edit or Addition)Kazuo Fujihara's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria (2011) (8941)
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (2017) (3544)
- A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis (2004) (2780)
- International consensus diagnostic criteria for neuromyelitis optica spectrum disorders (2015) (2486)
- Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. (2007) (595)
- Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. (2007) (581)
- Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo (2009) (515)
- MOG encephalomyelitis: international recommendations on diagnosis and antibody testing (2018) (483)
- MRI characteristics of neuromyelitis optica spectrum disorder (2015) (463)
- Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders (2014) (451)
- Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. (2012) (339)
- Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial (2019) (311)
- Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica (2005) (305)
- MOG cell-based assay detects non-MS patients with inflammatory neurologic disease (2015) (294)
- The Pathology of an Autoimmune Astrocytopathy: Lessons Learned from Neuromyelitis Optica (2014) (290)
- MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy (2017) (281)
- Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. (2019) (274)
- Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. (2019) (269)
- Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG (2006) (229)
- The investigation of acute optic neuritis: a review and proposed protocol (2014) (226)
- Treatment of Neuromyelitis Optica: Review and Recommendations. (2012) (220)
- Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography (2015) (204)
- Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica (2013) (193)
- Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders (2012) (171)
- Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity (2010) (171)
- Neuromyelitis Optica Spectrum Disorders. (2017) (170)
- Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide (2020) (160)
- Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients (2014) (156)
- Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations (2008) (154)
- MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder (2018) (153)
- Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination (2010) (152)
- Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis (2007) (151)
- Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years (2009) (150)
- Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. (2006) (149)
- A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset (2009) (136)
- Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling (2001) (136)
- Pure optic-spinal form of multiple sclerosis in Japan. (2002) (135)
- Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker (2009) (133)
- Myelin-oligodendrocyte glycoprotein antibody-associated disease (2021) (131)
- Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica (2010) (125)
- MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study (2015) (125)
- Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. (2020) (119)
- Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report. (2006) (113)
- Pain in neuromyelitis optica and its effect on quality of life (2011) (112)
- Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications (2016) (110)
- Astrocytic damage is far more severe than demyelination in NMO (2010) (109)
- Update on biomarkers in neuromyelitis optica (2015) (104)
- Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders (2019) (104)
- Influence of pregnancy on neuromyelitis optica spectrum disorder (2012) (102)
- Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum (2009) (101)
- Occurrence of acute large and edematous callosal lesions in neuromyelitis optica (2009) (96)
- Neuromyelitis optica spectrum disorders: still evolving and broadening (2019) (94)
- Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies (2017) (94)
- Leukoencephalopathy in HTLV-I-associated myelopathy/tropical spastic paraparesis: MRI analysis and a two year follow-up study after corticosteroid therapy (1991) (91)
- CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications (2018) (91)
- Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis (2008) (90)
- OSMS is NMO, but not MS: proven clinically and pathologically (2006) (88)
- Mercury chloride decreases the water permeability of aquaporin‐4‐reconstituted proteoliposomes (2008) (88)
- Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. (2020) (87)
- Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies (2016) (86)
- Pathogenic T cell responses against aquaporin 4 (2011) (84)
- Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders (2019) (81)
- Pregnancy outcomes in aquaporin-4–positive neuromyelitis optica spectrum disorder (2016) (81)
- Pain in neuromyelitis optica—prevalence, pathogenesis and therapy (2014) (80)
- Aquaporin-4 antibody–positive cases beyond current diagnostic criteria for NMO spectrum disorders (2013) (79)
- The MG‐QOL15 Japanese version: Validation and associations with clinical factors (2012) (78)
- Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology (2020) (77)
- Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease (2012) (77)
- Area postrema syndrome (2018) (76)
- Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations (2018) (74)
- T cell-activation in neuromyelitis optica lesions plays a role in their formation (2013) (73)
- Neuromyelitis optica and astrocytic damage in its pathogenesis (2011) (70)
- Health‐related quality‐of‐life and treatment targets in myasthenia gravis (2014) (69)
- CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis (2004) (69)
- Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels (2011) (69)
- Differential diagnosis of neuromyelitis optica spectrum disorders (2017) (67)
- Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody (2015) (67)
- Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica (2016) (65)
- Clinical and MRI study of brain stem and cerebellar involvement in Japanese patients with multiple sclerosis (1999) (65)
- A serological analysis of viral and bacterial infections associated with neuromyelitis optica (2011) (64)
- Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats (2013) (63)
- Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder (2016) (63)
- Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. (2015) (62)
- Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS (2015) (61)
- Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis (2014) (58)
- Placebo-controlled study in neuromyelitis optica—Ethical and design considerations (2015) (57)
- Fulminant demyelinating encephalomyelitis (2015) (56)
- Cerebrospinal Fluid Aquaporin-4 Antibody Levels in Neuromyelitis Optica Attacks (2014) (56)
- Clinical values of FDG PET in polymyositis and dermatomyositis syndromes: imaging of skeletal muscle inflammation (2015) (56)
- Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat (2018) (53)
- Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis (2004) (53)
- New therapies for neuromyelitis optica spectrum disorder (2020) (52)
- Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study (2011) (52)
- Natural killer (NK) cells in HTLV-I-associated myelopathy/tropical spastic paraparesis — decrease in NK cell subset populations and activity in HTLV-I seropositive individuals (1991) (52)
- Different etiologies and prognoses of optic neuritis in demyelinating diseases (2016) (51)
- Complementarity-Determining Region 3 Spectratyping Analysis of the TCR Repertoire in Multiple Sclerosis1 (2003) (49)
- Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder (2017) (49)
- Amplification of JC virus regulatory DNA sequences from cerebrospinal fluid: diagnostic value for progressive multifocal leukoencephalopathy (1998) (49)
- The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model (2015) (49)
- Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica (2013) (48)
- Familial neuromyelitis optica (Devic’s syndrome) with late onset in Japan (2000) (47)
- Treatment of MOG antibody associated disorders: results of an international survey (2020) (47)
- Treatment of neuromyelitis optica: an evidence based review. (2012) (44)
- Nationwide epidemiological study of neuromyelitis optica in Japan (2018) (42)
- Two subtypes of optic-spinal form of multiple sclerosis in Japan: clinical and laboratory features (2007) (42)
- The effects of 4-aminopyridine on motor evoked potentials in multiple sclerosis (1998) (42)
- Multiple sclerosis in Japan appears to be a milder disease compared to the UK (2015) (42)
- Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody (2015) (41)
- Two different clinical phenotypes of Creutzfeldt-Jakob disease with a M232R substitution (2007) (41)
- Linear pontine trigeminal root lesions in multiple sclerosis: clinical and magnetic resonance imaging studies in 5 cases. (2001) (41)
- Oligoclonal IgG bands in Japanese patients with multiple sclerosis. A comparative study between isoelectric focusing with IgG immunofixation and high-resolution agarose gel electrophoresis (2005) (40)
- Depressive state and chronic fatigue in multiple sclerosis and neuromyelitis optica (2015) (40)
- Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD (2016) (40)
- Heterogeneity and continuum of multiple sclerosis phenotypes in Japanese according to the results of the fourth nationwide survey (2009) (39)
- Clinical Spectrum and Treatment of Neuromyelitis Optica Spectrum Disorders: Evolution and Current Status (2013) (39)
- Two cases of lumbosacral myeloradiculitis with anti-aquaporin-4 antibody (2012) (39)
- Neuromyelitis optica preceded by hyperCKemia episode (2010) (38)
- Challenges and opportunities in designing clinical trials for neuromyelitis optica (2015) (38)
- Atypical presentations of neuromyelitis optica. (2011) (37)
- Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica (2016) (37)
- Influenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: a case report (2014) (36)
- Inflammatory demyelinating disease mimicking malignant glioma. (2003) (36)
- Demyelinating diseases in Asia. (2016) (36)
- High CSF neurofilament heavy chain levels in neuromyelitis optica (2006) (36)
- Neuromyelitis optica preceded by hyperCKemia episode (2010) (34)
- CSF-chemokines in HTLV-I-associated myelopathy: CXCL10 up-regulation and therapeutic effect of interferon-α (2005) (34)
- The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients (2016) (32)
- Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD) (2020) (32)
- Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies (2015) (32)
- Novel clinical grading of delayed neurologic sequelae after carbon monoxide poisoning and factors associated with outcome. (2015) (31)
- Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders (2020) (29)
- Absence of IgG1 response in the cerebrospinal fluid of relapsing neuromyelitis optica (2004) (29)
- Oral corticosteroid therapy and present disease status in myasthenia gravis (2015) (29)
- Clinical and laboratory features of neuromyelitis optica with oligoclonal IgG bands (2007) (29)
- Cellular immune surveillance against HTLV-I infected T lymphocytes in HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) (1991) (28)
- Seronegative Neuromyelitis Optica Spectrum--the challenges on disease definition and pathogenesis. (2014) (28)
- Significant correlation between IL-10 levels and IgG indices in the cerebrospinal fluid of patients with multiple sclerosis (2000) (28)
- Oligoclonal IgG bands in Japanese multiple sclerosis patients (1999) (28)
- Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder (2021) (27)
- Restoring immune tolerance in neuromyelitis optica (2016) (27)
- Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4 (2013) (26)
- Leber’s hereditary optic neuropathy mitochondrial DNA mutations in familial multiple sclerosis (1999) (26)
- Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis (2015) (25)
- Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD (2021) (25)
- Insights into the Classification of Myasthenia Gravis (2014) (25)
- Arg(184)his mutant GTP cyclohydrolase I, causing recessive hyperphenylalaninemia, is responsible for dopa‐responsive dystonia with parkinsonism: A case report (2004) (25)
- Frequency, criteria, and severity in AQP4-IgG–positive NMOSD (24)
- Revised Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders (S63.001) (2014) (24)
- A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica. (2008) (24)
- Eugène Devic (1858–1930) (2002) (24)
- Importance of the quotient of albumin, quotient of immunoglobulin G and Reibergram in inflammatory neurological disorders with disease‐specific patterns of blood–brain barrier permeability (2015) (24)
- Rapid Administration of High-Dose Intravenous Methylprednisolone Improves Visual Outcomes After Optic Neuritis in Patients With AQP4-IgG-Positive NMOSD (2020) (23)
- A comparative study of Japanese multiple sclerosis patients with and without oligoclonal IgG bands (2002) (23)
- Familial inclusion body myositis: a report on two Japanese sisters. (2003) (23)
- Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics. (2020) (23)
- Decrease in multiple sclerosis with acute transverse myelitis in Japan. (1999) (22)
- Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders. (2021) (22)
- CCR7+ myeloid dendritic cells together with CCR7+ T cells and CCR7+ macrophages invade CCL19+ nonnecrotic muscle fibers in inclusion body myositis (2009) (22)
- Elevated plasma level of plasminogen activator inhibitor-1 (PAI-1) in patients with relapsing-remitting multiple sclerosis. (1999) (22)
- Chemokine profile in the cerebrospinal fluid and serum of Vogt–Koyanagi–Harada disease (2005) (22)
- Whole brain and grey matter volume of Japanese patients with multiple sclerosis (2017) (22)
- Acute combined central and peripheral demyelination showing anti-aquaporin 4 antibody positivity. (2012) (21)
- Expression of OX40 in muscles of polymyositis and granulomatous myopathy (2002) (21)
- Features of anti-aquaporin 4 antibody-seronegative Thai patients with neuromyelitis optica spectrum disorders: A comparison with seropositive cases (2014) (21)
- [Neuromyelitis optica and anti-aquaporin 4 antibody--an overview]. (2008) (21)
- Sequential changes of cholinergic and dopaminergic receptors in brains after 6-hydroxydopamine lesions of the medial forebrain bundle in rats (2000) (21)
- Restoring immune tolerance in neuromyelitis optica (2016) (21)
- [Biomarkers in neuromyelitis optica]. (2012) (20)
- Relevance of callosal and periventricular MRI lesions to oligoclonal bands in multiple sclerosis (2006) (20)
- Fingolimod-associated PML with mild IRIS in MS (2017) (20)
- Successful treatment of a hypothalamic lesion in neuromyelitis optica by plasma exchange (2007) (20)
- Optic-spinal form of multiple sclerosis and anti-thyroid autoantibodies (1999) (20)
- Expression of CCR7 and its ligands CCL19/CCL21 in muscles of polymyositis (2006) (19)
- Spinal cord ring enhancement in patients with neuromyelitis optica (2015) (19)
- Myelin oligodendrocyte glycoprotein immunoglobulin G‐associated disease: An overview (2018) (19)
- [The MG-QOL15 Japanese version: validation and associations with clinical factors]. (2012) (19)
- Hypoxia-like tissue injury and glial response contribute to Balo concentric lesion development (2016) (18)
- Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India (2016) (18)
- [Anti-MOG + neuromyelitis optica spectrum disorders treated with plasmapheresis]. (2016) (18)
- Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria (2023) (17)
- Risk factors of attacks in neuromyelitis optica spectrum disorders (2020) (17)
- Anti–N‐methyl‐D‐aspartate receptor encephalitis with multiphasic demyelination (2014) (17)
- Taste disorders in myasthenia gravis: a multicenter cooperative study (2013) (17)
- Complement-dependent and -independent aquaporin 4-antibody-mediated cytotoxicity in human astrocytes: Pathogenetic implications in neuromyelitis optica (2016) (17)
- Complement activation as a cause of transient hypotension during plasmapheresis. (1998) (17)
- Neutralizing antibodies are associated with a reduction of interferon-β efficacy during the treatment of Japanese multiple sclerosis patients. (2012) (16)
- Th1/Th2 balance and HTLV-I proviral load in HAM/TSP patients treated with interferon-α (2004) (16)
- Neuromyelitis Optica (2010) (16)
- Modulation of dendritic cell development by immunoglobulin G in control subjects and multiple sclerosis patients (2007) (16)
- Alteration of cystatin C in the cerebrospinal fluid of multiple sclerosis (2007) (16)
- Serological markers associated with neuromyelitis optica spectrum disorders in South India (2016) (16)
- Experimental Neuromyelitis Optica Induces a Type I Interferon Signature in the Spinal Cord (2016) (15)
- The binding property of a monoclonal antibody against the extracellular domains of aquaporin-4 directs aquaporin-4 toward endocytosis (2016) (15)
- Treatment of MOG-IgG-associated demyelination with Rituximab: a multinational study of 98 patients (2018) (15)
- Cerebrospinal fluid CXCL13 is a prognostic marker for aseptic meningitis (2014) (15)
- Retracted: Alteration of cystatin C in the cerebrospinal fluid of multiple sclerosis (2007) (15)
- Increased cerebrospinal fluid osteopontin levels and its involvement in macrophage infiltration in neuromyelitis optica (2015) (15)
- Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. (2020) (15)
- Alteration of neurotensin receptors in MPTP-treated mice (1999) (15)
- Interferon-α significantly reduces cerebrospinal fluid CD4 cell subsets in HAM/TSP (2003) (15)
- Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders (2021) (14)
- Diagnosis and classification of optic neuritis (2022) (14)
- Clinical and physiological significance of abnormally prolonged central motor conduction time in HAM/TSP (2001) (14)
- Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder (2021) (13)
- Two Japanese cases of anti-MOG antibody-associated encephalitis that mimicked neuro-Behçet's disease (2019) (13)
- Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension (2021) (13)
- Lack of KIR4.1 autoantibodies in Japanese patients with MS and NMO (2016) (13)
- Patterns of regional brain volume loss in multiple sclerosis: a cluster analysis (2019) (13)
- A Case of Delayed Encephalopathy after Carbon Monoxide Poisoning Longitudinally Monitored by Diffusion Tensor Imaging (2012) (13)
- CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD (2020) (12)
- Genetic analysis of the aquaporin-4 gene for anti-AQP4 antibody-positive neuromyelitis optica in a Japanese population (2016) (12)
- Aquaporin-4 antibody-positive myelitis initially biopsied for suspected spinal cord tumors: Diagnostic considerations (2013) (12)
- Japanese cases of neuromyelitis optica spectrum disorder associated with myasthenia gravis and a review of the literature (2014) (12)
- Seronegative NMO (2013) (12)
- Cognitive impairment in neuromyelitis optica spectrum disorders: A comparison of the Wechsler Adult Intelligence Scale-III and the Wechsler Memory Scale Revised with the Rao Brief Repeatable Neuropsychological Battery (2017) (11)
- Efficacy of satralizumab (SA237) in subgroups of patients in SAkuraSky: a Phase III double-blind, placebo-controlled, add-on study in patients with neuromyelitis optica spectrum disorder (NMOSD) (S43.008) (2019) (11)
- Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy. (2021) (11)
- Secondary progression and innate immunity in NMO (2014) (11)
- Clinical and laboratory features of myelitis patients with anti-neutrophil cytoplasmic antibodies (1998) (11)
- [Neuromyelitis optica(Devic disease) and optic-spinal form multiple sclerosis]. (2001) (11)
- Human Parvovirus B19 Infection in Multiple Sclerosis (1999) (11)
- Dendritic cells in muscle lesions of sarcoidosis. (2011) (11)
- Expression of OX40 and OX40 ligand (gp34) in the normal and myasthenic thymus (2000) (11)
- HTLV-associated diseases: human retroviral infection and cutaneous T-cell lymphomas. (1997) (10)
- AQP4 antibody serostatus (2013) (10)
- Audiological evidence of therapeutic effect of steroid treatment in neuromyelitis optica with hearing loss (2014) (10)
- White blood cell count profiles in multiple sclerosis during attacks before the initiation of acute and chronic treatments (2021) (10)
- TNF-beta produced by human T lymphotropic virus type I-infected cells influences the proliferation of human endothelial cells and fibroblasts. (1994) (10)
- Serum AQP4-IgG level is associated with the phenotype of the first attack in neuromyelitis optica spectrum disorders (2020) (10)
- A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica) (2013) (10)
- Anti-MOG (Myelin Oligodendrocyte Glycoprotein)–Positive Severe Optic Neuritis with Optic Disc Ischaemia and Macular Star (2015) (9)
- Distinctive lesions of brain MRI between MOG-antibody-associated and AQP4-antibody-associated diseases (2020) (9)
- MOG-IgG serological status matters in paediatric ADEM (2014) (9)
- Neuromyelitis optica without typical opticospinal phenotype (2010) (9)
- MOG-antibody-associated disease is different from MS and NMOSD and should be classified as a distinct disease entity – Commentary (2019) (9)
- Therapeutic efficacy of interferon β-1b in Japanese patients with optic-spinal multiple sclerosis. (2011) (9)
- Cutaneous T-cell lymphoma, tropical spastic paraparesis, cerebral vasculitis, and protein S deficiency in a patient with HTLV-I. (1996) (9)
- Progressive multifocal leukoencephalopathy in a patient with acquired immunodeficiency syndrome (AIDS) manifesting Gerstmann's syndrome. (1998) (9)
- A novel monoclonal antibody against the C-terminal region of aquaporin-4. (2013) (9)
- Soluble CD26 and CD30 levels in CSF and sera of patients with relapsing neuromyelitis optica (2005) (9)
- Increases in [3H]FK-506 and [3H]L-NG-Nitro-Arginine Binding in the Rat Brain After Nigrostriatal Dopaminergic Denervation (1999) (9)
- [Neuromyelitis optica and anti-aquaporin 4 antibody--distinct from multiple sclerosis]. (2009) (8)
- Efficacy of methylprednisolone pulse therapy for acute relapse in Japanese patients with multiple sclerosis and neuromyelitis optica: A multicenter retrospective analysis – 1. Whole group analysis (2013) (8)
- Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease. (2021) (8)
- Interferon-alpha significantly reduces cerebrospinal fluid CD4 cell subsets in HAM/TSP. (2003) (8)
- Impact of the Great East Japan Earthquake in 2011 on MS and NMOSD: a study in Sendai, Japan (2016) (8)
- Altered white matter metabolism in delayed neurologic sequelae after carbon monoxide poisoning: A proton magnetic resonance spectroscopic study (2016) (8)
- Measurements of the corpus callosum index and fractional anisotropy of the corpus callosum and their cutoff values are useful to assess global brain volume loss in multiple sclerosis. (2020) (8)
- Relapsing focal myositis: the localization detected by gallium citrate Ga 67 scintigraphy. (2005) (8)
- [Clinical features of Japanese pediatric patients with anti-aquaporin 4 antibody]. (2011) (7)
- Novel compound tetra-, dinucleotide microsatellite polymorphism in the tumor necrosis factor/lymphotoxin locus (1997) (7)
- Antibody-dependent cell-mediated cytotoxicity (ADCC) in HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) (1996) (7)
- Neuro‐Behçet's disease presenting initially as mesiotemporal lesions mimicking herpes simplex encephalitis (2005) (7)
- A case of pathology-proven neuromyelitis optica spectrum disorder with Sjögren syndrome manifesting aphasia and apraxia due to a localized cerebral white matter lesion (2014) (7)
- Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD (2021) (7)
- Seasonal variation of onset in patients with anti-aquaporin-4 antibodies and anti-myelin oligodendrocyte glycoprotein antibody (2020) (7)
- Transient Pulmonary Interstitial Lesions in Aquaporin-4-positive Neuromyelitis Optica Spectrum Disorder (2018) (7)
- AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. (2021) (7)
- [A case of multiple intracranial tuberculoma diagnosed by open brain biopsy]. (1997) (7)
- Pathological study of subacute autoimmune encephalopathy with anti-AQP4 antibodies in a pregnant woman (2012) (7)
- Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders (2020) (6)
- High avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporin‐4 competing with the neuromyelitis optica autoantibody, NMO‐IgG (2015) (6)
- The investigation of acute optic neuritis (2014) (6)
- GRP78 Antibodies Are Associated With Blood-Brain Barrier Breakdown in Anti–Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disorder (2021) (6)
- A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as add-on therapy for neuromyelitis optica spectrum disorder (NMOSD) (2018) (6)
- Gamma–aminobutyric acidA and benzodiazepine receptor alterations in the rat brain after unilateral 6-hydroxydopamine lesions of the medial forebrain bundle (2002) (6)
- Long-term outcome of a group of Japanese children with myelin-oligodendrocyte glycoprotein encephalomyelitis without preventive immunosuppressive therapy (2019) (6)
- Induction of aquaporin 4-reactive antibodies in Lewis rats immunized with aquaporin 4 mimotopes (2020) (6)
- CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder (2021) (5)
- Long-term safety and effectiveness of eculizumab in neuromyelitis optica spectrum disorder (2019) (5)
- Lambert-Eaton myasthenic syndrome associated with an anterior mediastinal small cell carcinoma. (2001) (5)
- Patterns of cortical grey matter thickness reduction in multiple sclerosis (2020) (5)
- A new human endogenous DNA sequence homologous to HTLV-I pol. (1994) (5)
- Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders (2021) (5)
- Neuroimmunology: Towards more-accurate diagnosis in neuromyelitis optica (2014) (5)
- [NMO spectrum disorders and anti AQP4 antibody]. (2013) (5)
- Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease (2021) (5)
- Epitope analysis of the cerebrospinal fluid IgG in HTLV-I associated myelopathy patients using phage display method (2004) (5)
- Patient-reported burden of symptoms in neuromyelitis optica: A secondary analysis on pain and quality of life (2021) (5)
- A Double-masked, Placebo-controlled Study with Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adult Subjects with Neuromyelitis Optica Spectrum Disorders–Top line efficacy and safety results (Plen02.001) (2019) (5)
- Neuromyelitis optica spectrum and myelin oligodendrocyte glycoprotein antibody‐related disseminated encephalomyelitis (2018) (4)
- Epitope Analysis of Cerebrospinal Fluid IgG in Japanese Multiple Sclerosis Patients Using Phage Display Method (2011) (4)
- RGMa Signal in Macrophages Induces Neutrophil‐Related Astrocytopathy in NMO (2022) (4)
- Impact of eculizumab on reported quality of life in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the PREVENT study (2019) (4)
- Impact of intrathecal IgG synthesis on neurological disability in patients with multiple sclerosis. (2020) (4)
- Marked Increase of CSF GFAP in neuromyelitis optica: An astrocytic damage marker (2008) (4)
- [Treatment of neuromyelitis optica]. (2012) (3)
- Pharmacokinetic/pharmacodynamic properties of eculizumab support established efficacy in patients with NMOSD: findings from the phase 3 PREVENT study (2020) (3)
- Myelin oligodendrocyte glycoprotein immunoglobulin G‐associated disease (2020) (3)
- AQP4 in biopsied demyelinating lesions as a diagnostic clue to NMOSD and MS (2015) (3)
- Long-term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder (2020) (3)
- BENEFIT 8-year results provide further support for the long-term value of early treatment of multiple sclerosis (2014) (3)
- The prevalence and characteristics of neuromyelitis optica in Japan: A nationwide epidemiological study (2017) (3)
- Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series. (2022) (3)
- Anti-myelin Oligodendrocyte Glycoprotein Antibodies in a Patient with Recurrent Optic Neuritis Involving the Cerebral White Matter and Brainstem. (2016) (3)
- Number of MRI T1-hypointensity corrected by T2/FLAIR lesion volume indicates clinical severity in patients with multiple sclerosis (2020) (3)
- A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as add-on therapy for neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD) (2018) (3)
- Efficacy of satralizumab in subgroups of patients in SAkuraSky: A phase III double-blind, placebo-controlled, add-on study in patients with neuromyelitis optica spectrum disorder (NMOSD) (2019) (3)
- Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD (2022) (3)
- A case of NMO seropositive for aquaporin-4-antibody over 10 years before the onset (2009) (2)
- Optic-spinal form of multiple sclerosis and immune-mediated myelopathy in Japan. (2000) (2)
- MS Across Continents: Challenging our Knowledge of MS in Asia and the Middle East. Report from the 2nd MS Forum Pan-Asian Conference, 19-20 November 2004, Ho Chi Minh City, Vietnam. (2005) (2)
- [New insights into the pathogenesis of neuromyelitis optica]. (2010) (2)
- [Tetany as a sole manifestation in a patient with Bartter's syndrome and a successful treatment with indomethacin]. (1990) (2)
- Case of autoantibodies against N‐methyl‐D‐aspartate receptor+/antibodies against myelin‐oligodendrocyte glycoprotein+ multiphasic acute disseminated encephalomyelitis (ADEM) (2014) (2)
- Comparison of the Rao Brief Repeatable Neuropsychological Battery with Wechsler Adult Intelligence Scale‐III and Wechsler Memory Scale‐Revised in Japanese patients with multiple sclerosis (2015) (2)
- Quotient of cerebrospinal fluid/serum immunoglobulin G as a predictive factor for non‐responders to intravenous methylprednisolone therapy in patients with relapsing neuromyelitis optica spectrum disorder: Implication for early initiation of plasmapheresis (2016) (2)
- Impact of eculizumab on disability measures in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: phase 3 PREVENT study (2019) (2)
- [Pathogenetic significance of HTLV-I infection and immune surveillance in HAM]. (1999) (2)
- Candidate antigens specifically detected by cerebrospinal fluid‐IgG in oligoclonal IgG bands‐positive multiple sclerosis patients (2007) (2)
- Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. (2021) (2)
- [Magnetic resonance imaging for the diagnosis of multiple sclerosis]. (2003) (2)
- [Tremor-like pathological grasp phenomenon--a case report]. (1988) (2)
- Efficacy of Satralizumab (SA237) As Add-on Therapy in Pre-Specified Additional Analyses of Sakurasky, a Double-Blind Placebo-Controlled Phase 3 Study in Patients with Neuromyelitis Optica Spectrum Disorders (NMOSD) (2019) (2)
- 0554 An autopsied case of Neuromyelitis Optica with a large cavitary cerebral lesion (2005) (2)
- [A case of myelitis with anti-aquaporin 4 antibody concomitant with immune thrombocytopenic purpura]. (2014) (2)
- Long-term Efficacy of Satralizumab in AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar (2022) (2)
- [Epidemiology and clinical features of optic-spinal form multiple sclerosis in Japan]. (2001) (2)
- [Chemokines and chemokine receptors in multiple sclerosis]. (2003) (1)
- Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats (2013) (1)
- Efficacy and Safety of Eculizumab in Asian Patients WithAquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder: Subgroup Analysis From the Phase 3 PREVENT Study (2020) (1)
- Relapse of Neuromyelitis Optica Associated with Pregnancy Is More Frequently Than That for Multiple Sclerosis (P02.126) (2013) (1)
- Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from the Phase 3 PREVENT Study (1788) (2020) (1)
- Early Treatment Initiation With Oral Prednisolone for Relapse Prevention Alleviates Depression and Fatigue in Aquaporin-4–Positive Neuromyelitis optica Spectrum Disorder (2021) (1)
- Comment: Sensitivity and clinical relevance of available anti-aquaporin-4 antibody assays (2012) (1)
- A Response to: Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder” (2022) (1)
- T cell-activation in neuromyelitis optica lesions plays a role in their formation (2013) (1)
- Impact of eculizumab on hospitalization rates and relapse treatment in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the phase 3 PREVENT study (2019) (1)
- Leukoencephalopathy resolution after atypical mycobacterial treatment: a case report (2015) (1)
- Debate on the treatment of multiple sclerosis: Experience from an intractable multiple sclerosis case with rebound syndrome after fingolimod cessation (2019) (1)
- Erratum: Mercury chloride decreases the water permeability of aquaporin-4-reconstituted proteoliposomes (Biology of the Cell (2008) vol. 100 (6) (355-363)) (2008) (1)
- [Clinical concept, etiology and pathology of neuromyelitis optica]. (2014) (1)
- [A concept of neuromyelitis optica in Japan]. (2010) (1)
- Long-term Safety and Efficacy of Eculizumab in Asian Patients With Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder (2020) (1)
- Multiple sclerosis patients in Japan appear to have less disability compared to the UK (2013) (1)
- Remarkable effect of anticoagulation therapy in Churg–Strauss syndrome‐associated neuropathy: a case report (2006) (1)
- Acute callosal disconnection syndrome as an initial manifestation of neuromyelitis optica spectrum disorders (2015) (1)
- Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from the Phase 3 PREVENT Study (1788) (2020) (1)
- Pseudo-perifascicular atrophy in the healing phase of Jo-1 antisynthetase syndrome (2016) (1)
- [Current Status and Prospects of Complement-Targeting Therapy for Neuromyelitis Optica]. (2019) (1)
- [Pathogenesis of optic-spinal MS]. (2002) (1)
- Long-term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder (1494) (2020) (1)
- Severe aquaporin 4-IgG-positive neuromyelitis optica with disseminated herpes zoster in a pregnant woman successfully treated with intravenous immunoglobulin (2018) (1)
- Acute retrobulbar optic neuritis with anti-myelin oligodendrocyte glycoprotein antibody-associated disease complicated with microscopic polyangiitis (2021) (1)
- Long-term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder (1494) (2020) (1)
- [Pathogenesis of neuromyelitis optica]. (2013) (1)
- Subgroup analyses from the Phase 3 PREVENT study in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (2019) (1)
- Neuromyelitis Optica Spectrum Disorders in Africa (A Narrative Review of 622 Cases) (2022) (0)
- Long-Term Eculizumab in AQP4+ NMOSD: Relapse-Risk Reduction and Safety in PREVENT and its Completed Open-Label Extension (2022) (0)
- [Multiple sclerosis and oligoclonal IgG bands]. (2004) (0)
- Depressive State and Chronic Fatigue in Neuromyelitis Optica. (P5.255) (2015) (0)
- Long-term Efficacy of Satralizumab in Adults with Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from SAkuraMoon (S5.001) (2023) (0)
- Pathogenesis of NMOSD (2017) (0)
- Short communication Chemokine profile in the cerebrospinal fluid and serum of Vogt-Koyanagi-Harada disease (2005) (0)
- New Insights, Promises and Challenges (2013) (0)
- Teaching Course 12 Neuromyelitis Optica Spectrum Disorders (2015) (0)
- [Current and historical concept of neuromyelitis optica]. (2015) (0)
- Autoimmune encephalitis in patients with anti-myelin oligodendrocyte glycoprotein-antibody (2017) (0)
- Author response. (2014) (0)
- Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial (2022) (0)
- CENTRAL MOTOR AND SENSORY CONDUCTION TIMES IN HAM/TSP (1999) (0)
- Brainstem Manifestations in Neuromyelitis Optica (P02.144) (2013) (0)
- Preparation and Clinical Application of the 4-Aminopyridine Capsule as a Hospital Preparation. (2000) (0)
- Astrocyte lesion and secondary demyelination: The lesson from neuromyelitis optica (2011) (0)
- Causal background factors for depressive state in myasthenia gravis patients: a multicenter cooperative study (2011) (0)
- Impact of Eculizumab on Health Outcomes in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Findings from the PREVENT Study (2020) (0)
- Optic neuritis after ocular trauma in anti‐aquaporin‐4 antibody‐positive neuromyelitis optica spectrum disorder (2021) (0)
- [Pathogenesis of Neuromyelitis Optica: aquaporin 4 autoimmunity and astrocytopathy]. (2010) (0)
- Impact of Eculizumab on Disability Worsening and Quality of Life in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Results from the Phase 3 PREVENT Study (1658) (2020) (0)
- Clinical Features of Japanese Patients with Myasthenia Gravis Associated with Autoimmune Thyroid Diseases (P02.203) (2013) (0)
- Short communication Interferon-a significantly reduces cerebrospinal fluid CD4 cell subsets in HAM/TSP (2003) (0)
- Difference of anti‐viral immunity induced by two mRNA vaccines: Implications in MS patients treated with anti‐CD20‐depleting therapy (2021) (0)
- 2017 Japanese guidelines for multiple sclerosis and neuromyelitis optica: Achievements and challenges (2018) (0)
- Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids. (2023) (0)
- A novel association of osmotic demyelination in Sjögren's syndrome prompts revisiting role of aquaporins in CNS demyelinating diseases: A literature review. (2022) (0)
- Autoantibodies in central nervous system and neuromuscular autoimmune disorders: A narrative review (2022) (0)
- Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody (2015) (0)
- Insights into the Classification of Myasthenia Gravis. (P5.037) (2015) (0)
- Anti-MOG Antibodies in Japanese Patients with Neuromyelitis Optica Spectrum Disorders (2014) (0)
- Congress report of the 9th Pan‐Asian Committee for Treatment and Research in Multiple Sclerosis (2017) (0)
- Long-term efficacy and safety of eculizumab in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (2021) (0)
- Seasonal Variation of Relapses in Neuromyelitis Optica (2012) (0)
- Update on treatment of the other demyelinating diseases (2021) (0)
- Author response. (2014) (0)
- Severe Sequelae of Group B Streptococcal (Streptococcus Agalactiae) Meningitis in an 82‐year‐old Man (2001) (0)
- PREGNANCY OUTCOME IN AQUAPORIN-4 POSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDER: A MULTI-CENTER RETROSPECTIVE COHORT STUDY (2014) (0)
- [Clinical subtypes of multiple sclerosis and the immuno-pathogeneses]. (2003) (0)
- [Multiple sclerosis--recent advances in pathogenesis and treatment]. (2002) (0)
- The Effect of NMO-IgG and Complement Against Primary Human Astrocytes in Culture (P02.132) (2012) (0)
- Children with myelin oligodendrocyte glycoprotein antibodies‐associated disease: relation of phenotypes to central nervous system myelin maturation (2018) (0)
- Safety and Effectiveness of Eculizumab in Japanese Patients With Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance Study (2022) (0)
- [Anti-aquaporin-4 (AQP4) antibody]. (2010) (0)
- NMO Onset Is More Rapid in North American Ethnic East Asians Compared to Caucasians (P02.153) (2013) (0)
- [A juvenile case of Lambert-Eaton myasthenic syndrome with severe emaciation]. (1997) (0)
- Short communication Th1/Th2 balance and HTLV-I proviral load in HAM/TSP patients treated with interferon-a (2004) (0)
- T CELL SUBSETS IN CULTURED LYMPHOCYTES IN HAM/TSP IN COMPARISON WITH PHA-INDUCED LYMPHOCYTE PROLIFERATION (1999) (0)
- Impact of Eculizumab on Hospitalization Rates and Relapse Treatment in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: the Phase 3 PREVENT Study (2020) (0)
- Clinical phenotypes of pediatric and adult patients with anti-MOG antibodies (2015) (0)
- [Steroid-responsive diffuse cerebral white matter lesions in a case of intractable fungal meningoencephalitis]. (1999) (0)
- Neuromyelitis Optica Relapse Associated with Pregnancy: Similarities to Multiple Sclerosis (P06.184) (2012) (0)
- Perivenous demyelination: Association with anti‐myelin oligodendrocyte glycoprotein antibody (2020) (0)
- The impact of neuromyelitis optica spectrum disorder on pregnancy outcome (2014) (0)
- Our current understanding of neuromyelitis optica and its spectrum (2015) (0)
- Practical issues and new horizons in MS, NMOSD and related disorders (2017) (0)
- A Multicentric Cross-sectional Study of the Usefulness of Cerebrospinal Fluid-Glial Fibrillary Acidic Protein (CSF-GFAP) in the Diagnosis and Prognosis of Inflammatory Demyelinating Diseases (P4.133) (2014) (0)
- Stratifying Patients at Risk for Neurologic Sequelae after Carbon Monoxide Poisoning by Monitoring Serum Bilirubin Response (S47.001) (2012) (0)
- Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD (2016) (0)
- [110th Scientific Meeting of the Japanese Society of Internal Medicine: Educational lecture: 11. Multiple sclerosis (MS) and neuromyelitis optica (NMO)]. (2013) (0)
- [Laboratory findings in optic-spinal multiple sclerosis]. (2006) (0)
- Contrast-enhanced double inversion recovery sequence for patients with multiple sclerosis: feasibility of subtraction images between pre- and post-contrast images (2022) (0)
- Brain atrophy in Japanese patients with multiple sclerosis (2017) (0)
- Impact Of Eculizumab On Quality Of Life In AQP4+NMOSD: Findings From The PREVENT Study (2020) (0)
- White blood cell count profiles in anti-aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder and anti-myelin oligodendrocyte glycoprotein antibody-associated disease (2023) (0)
- Induction of aquaporin 4-reactive antibodies in Lewis rats immunized with aquaporin 4 mimotopes (2020) (0)
- The effect of complement of different species against human primary astrocyte (2011) (0)
- Inflammatory demyelinating polyneuropathy with nephrotic syndrome: Report of a case and review of the literature (2013) (0)
- Erratum (2015) (0)
- Time-Dependent Analysis of Sicca Symptoms and Anti-Ro/SSA and Anti-La/SSB Antibodies in Patients with AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder. (2023) (0)
- Efficacy and safety of eculizumab in aquaporin-4-antibody-positive neuromyelitis optica spectrum disorder: A phase 3, randomized, double-blind, placebo-controlled, multicenter trial (PREVENT) (2019) (0)
- Prevalence and clinical characteristics of neuromyelitis optica spectrum disorders patients with myelin oligodendrocyte glycoprotein antibodies (2013) (0)
- Myelin olygodendorocyte glycoprotein-antybody-associated neurologic disease – an adult case series at a Fukushima Hospital (2017) (0)
- Neuromyelitis Optica Spectrum with Autoantibodies Against Myelin-Oligodendrocyte Glycoprotein Have Distinct Clinical Features and Prognosis from Seronegative Patients (S63.006) (2014) (0)
- 3P-212 Mercury Chloride Decreases the Water Permeability of Aquaporin-4-Reconstituted Proteoliposomes(The 46th Annual Meeting of the Biophysical Society of Japan) (2008) (0)
- requirements by permitting unilateral optic neuritis or asymptomatic brain MRI lesions (0)
- Immunological Analysis of MOG autoantibody positive NMOSD and aquaporin-4 autoantibody positive NMOSD (P5.252) (2015) (0)
- NMO-IgG as Measured in Multiple Facilities in Optic Neuritis (ON), Transverse Myelitis (TM) and Combinations Thereof (P02.130) (2012) (0)
- Impact of Eculizumab on Disability Worsening and Quality of Life in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Results from the Phase 3 PREVENT Study (1658) (2020) (0)
- Application of diagnostic criteria for optic neuritis – Authors' reply (2023) (0)
- Familial Creutzfeldt-Jakob disease with a point mutation (Met to Arg) at codon 232: two different phenotypes (2005) (0)
- A large international aquaporin-4 antibody data set: combines individual factors to predict prognosis, identifies the risk of post-onset attack disability and calculates the power for future clinical trials (2019) (0)
- Benefit of Eculizumab for a Broad Range of Patients with Aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: Findings from the Phase 3 PREVENT Study (1299) (2020) (0)
- SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab (2023) (0)
- Pregabalin attenuates dysautonomia as well as painful dysesthesia caused by Guillain–Barré syndrome (2013) (0)
- Utility of Non-Conventional MRI in Assessing White Matter Damage after Carbon Monoxide Poisoning (P5.338) (2014) (0)
- Clinical features of sarcoid myelopathy focusing on age, distribution, and concomitant spinal disease (2014) (0)
- [Update on the etiology and pathogenesis of multiple sclerosis and neuromyelitis optica]. (2008) (0)
- 7 Apheresis in neuromyelitis optica (2010) (0)
- The Importance of Aquaporin-4 Antibody Assays in Patients beyond the Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders (2013) (0)
- [Cognitive impairment in demyelinating disease]. (2011) (0)
- [Neuromyelitis optica: the disease entity, pathogenesis and therapy]. (2007) (0)
- [Transverse myelopathy with renovascular hypertension caused by fibromuscular dysplasia]. (2001) (0)
- POSA8 Indirect Comparison Analysis of United States Food and Drug Administration-Approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder (2022) (0)
- Benefit of Eculizumab for a Broad Range of Patients with Aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: Findings from the Phase 3 PREVENT Study (1299) (2020) (0)
- Autoantibodies against MOG in Neuromyelitis Optica Spectrum Disorders (2015) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Kazuo Fujihara?
Kazuo Fujihara is affiliated with the following schools:
